Holocene Advisors
PTGX icon

Holocene Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Holocene Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.1M Sell
209,916
-103
-0% -$9.12K 0.05% 260
2025
Q4 		$18.3M Buy
+210,019
New +$17.2M 0.04% 291
2025
Q3 		– Sell
-530,326
Closed -$29.3M – 885
2025
Q2 		$29.3M Buy
+530,326
New +$25.5M 0.07% 215
2023
Q3 		– Sell
-802,531
Closed -$22.2M – 851
2023
Q2 		$22.2M Buy
+802,531
New +$20.1M 0.09% 203

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Holocene Advisors's PTGX Position: Q1 2026 in Review

Holocene Advisors reduced its Protagonist Therapeutics (PTGX) stake by 0.05% in Q1 2026, selling an estimated $9.12K and leaving 209,916 shares worth $22.1M. The position accounts for 0.05% of the portfolio, ranked #260.

Holocene Advisors first reported a position in PTGX in Q2 2023 and has held it in 4 quarters since. The position peaked at $29.3M in Q2 2025. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Holocene Advisors held 209,916 shares of Protagonist Therapeutics worth $22.1M as of Q1 2026.
  • Holocene Advisors sold 103 Protagonist Therapeutics shares in Q1 2026, an estimated $9.12K.
  • Protagonist Therapeutics made up 0.05% of Holocene Advisors's portfolio in Q1 2026, its #260 holding.
  • Holocene Advisors first reported a position in Protagonist Therapeutics in Q2 2023 and has held it in 4 quarters since.
  • Holocene Advisors's Protagonist Therapeutics position peaked at $29.3M in Q2 2025.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Holocene Advisors's 13F filing for Q1 2026, filed 15 May 2026.